New Advances in iPS Cell Research Do Not Obviate the Need for Human Embryonic Stem Cells  by Hyun, Insoo et al.
Cell Stem Cell
CorrespondenceNewAdvances in iPSCellResearchDoNotObviate
the Need for Human Embryonic Stem Cells
Insoo Hyun,1,* Konrad Hochedlinger,2 Rudolf Jaenisch,3,4 and Shinya Yamanaka5,6
1Department of Bioethics, CaseWestern Reserve University School ofMedicine, 10900 Euclid Avenue, Cleveland, OH 44106-4976,
USA
2Massachusetts General Hospital Cancer Center and Center for Regenerative Medicine, Harvard Stem Cell Institute,
185 Cambridge Street, Boston, MA 02114, USA
3Whitehead Institute for Biomedical Research
4Department of Biology
Massachusetts Institute of Technology, 9 Cambridge Center, Cambridge, MA 02142, USA
5Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
6CREST, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan
*Correspondence: insoo.hyun@case.edu
DOI 10.1016/j.stem.2007.09.006Recently three different studies were
published demonstrating that mouse
fibroblast (skin) cells can be directly re-
programmed to behave like embryonic
stem cells (Okita et al., 2007; Wernig
et al., 2007; Maherali et al., 2007).
These studies advanced a break-
through announced last year in which
a quartet of genes (Oct-3/4, Sox2,
c-Myc, and Klf4) were discovered to
induce pluripotency in mouse cells,
albeit incompletely (Takahashi and Ya-
manaka, 2006). Now a second genera-
tion of these induced pluripotent stem
cells (called iPS cells) has been made
to do almost everything mouse embry-
onic stem cells can do. When mouse
iPS cells were injected into mouse
blastocysts, they contributed to all tis-
sue types in the resulting adult mice,
including sperm and oocytes (Okita
et al., 2007; Wernig et al., 2007;
Maherali et al., 2007). And one re-
search team produced fetal mice de-
rived entirely from iPS cells—a key
criterion for embryonic stem cells
(Wernig et al., 2007).
Media reports of these stem cell ad-
vances have enlivened the public’s
hopes of one day producing human
iPS cells from collected skin biopsies
to generate patient-specific stem cells
for disease research, drug develop-
ment, and new cell-based therapies.
Consequently, some policymakers
and citizens might be tempted to
jump to the conclusion that research
on human embryonic stem cells (hES
cells) is unnecessary in light of the
emerging possibility of human iPS
cell research. Indeed, this misguidedimpression could be further fueled by
President Bush’s latest stem cell bill
veto, at which time he referred to these
new stem cell studies as a galvanizing
reason for his opposition to hES cell
research and part of his motive for is-
suing an executive order to provide
public funds for ‘‘alternative’’ forms of
human stem cell research (Associated
Press, 2007; Department of Health and
Human Services, NIH, 2007).
However, it would be a serious mis-
take to conclude that recent develop-
ments in iPS cell research (or, for that
matter, any other so-called ‘‘alterna-
tive’’ source of pluripotent stem cells)
avert the need for ongoing research
on hES cells. There are many impor-
tant reasons why iPS cell research
must be conducted hand in hand with
hES cell research. In advancing these
reasons we do not mean to imply that
hES cell research is not of paramount
importance in its own right. There are
overwhelming scientific justifications
for proceeding with hES cell research,
which is precisely why it is important
for the public to maintain a realistic
perspective on iPS cell research vis-
a`-vis hES cell research.
First, progress toward socially bene-
ficial applications of stem cell science
would be indefensibly delayed if iPS
cell research is pursued at the expense
of further hES cell research. Research
on iPS cells has barely begun, and
there is much to learn. For example,
tumorigenicity and safety are major
concerns for iPS cells, as one of the
pluripotency-inducing transcription
factors, c-Myc, seemed to contributeCell Stem Cellto cancer in 20% of chimeric mice
(Okita et al., 2007). Even if c-Myc could
be substituted, the retroviruses used
to insert the pluripotency-inducing
factors might themselves lead to
cancer and deleterious mutations. Al-
though the current research suggests
that retroviruses are needed only to
activate skin cells’ change to iPS cells,
and that endogenous genes seem to
maintain pluripotency thereafter, it is
unclear at this point whether other
modifications will be necessary and
what limitations these modifications
may pose for possible therapeutic
applications. The fact that all mouse
iPS cell clones contain numerous inte-
grations of retroviruses suggests that
activation or inactivation of additional
genes may be required for their induc-
tion. Thus it could take many years to
understand fully what iPS cells are ca-
pable of doing. All the while, hES cells
are currently available and should be
used for research that may produce
important translational scientific work
from the bench to the bedside. There-
fore, hES cell research should not be
fettered or slowed down, especially
during this time at which the unique
challenges facing iPS cell research
remain unresolved.
Second, there is the related point
that, despite tremendous efforts, iPS
cell research might not translate to
human cells. To date, iPS cells have
only been generated in experimental
mice. There may be significant and un-
foreseen differences between mice
and humans that may prevent human
body cells from being similarly1, October 2007 ª2007 Elsevier Inc. 367
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transformation, mouse fibroblasts
can be transformedwith two active on-
cogenes, but human fibroblasts re-
quire four or more oncogenes. Recall
that it took 15 years of research to
identify the genetic differences be-
tween human and mouse cancer cells
and even longer between the isolation
of mouse and human ES cells. It is
therefore unpredictable when, if at all,
human iPS cells will be generated.
From a public policy standpoint aimed
at advancing responsible science,
prudence calls for ongoing hES cell re-
search, as human iPS cell research
may not succeed.
Third, in the felicitous event that hu-
man iPS cells are generated in due
course, hES cells will have to be used
as important controls to examine the
safety and abilities of human iPS cells.
In the case of mouse iPS cells, we
(K.H., R.J., and S.Y., unpublished
data) were able to improve the selec-
tionmethod by using ES cells as a con-
trol. It must be emphasized that at
present ES cells derived from embryos
represent the only pluripotent cells
that are genetically unmodified. In the
course of early human iPS cell re-
search, up-to-date knowledge of hES
cells will be essential for informing sci-368 Cell Stem Cell 1, October 2007 ª200entists’ understanding and analyses of
human iPS cells.
Fourth, even if human iPS cells are
derived, there are invaluable avenues
of research that may not be easily pur-
sued with reprogrammed skin cells.
For example, early postimplantation
development of the human embryo
is experimentally difficult to access.
In vitro differentiation of hES cells rep-
resents a unique experimental system
to study early stages of human devel-
opment.
Thus, we hold that research into all
avenues of human stem cell research
must proceed together. Society de-
serves to have the full commitment of
scientific inquiry at its service. And sci-
ence is a practice that works best
when it is approached with an open
and creative mind. Research into one
approach can inspire new ideas in un-
predictable and exciting ways. As
a case in point, the inspiration for iPS
cell research came from an earlier
stem cell study in which human body
cells were reprogrammed by fusion
with hES cells (Cowan et al., 2005).
From this earlier study it was hypothe-
sized that hES cells have defined fac-
tors that induce pluripotency, thus
leading to the first iPS cell break-
through in 2006 (Takahashi and Yama-7 Elsevier Inc.naka, 2006). In short, the recent ad-
vancements in iPS cell research
would not be possible if it were not
for the many years of dedicated hES
cell research that preceded them. We
cannot support the notion that iPS
cell research can advance without
hES cell research.
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